Interstitial lung disease

References

• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. doi:10.1056/NEJMoa1402584.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM. Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Rev Respir Med. 2011;5(4):473–481. doi:10.1586/ers.11.52.
   PubMed Web of Science ®Google Scholar
• King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092. doi:10.1056/NEJMoa1402582.
   PubMed Web of Science ®Google Scholar
• Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020;55(6):2000085. doi:10.1183/13993003.00085-2020.
   PubMed Web of Science ®Google Scholar
• Nasser M, Larrieu S, Si-Mohamed S, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS(R) study). Eur Respir J. 2021;57(2):2002718. doi:10.1183/13993003.02718-2020.
   Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36–e69. doi:10.1164/rccm.202005-2032ST.
   PubMed Web of Science ®Google Scholar
• Kheir F, Alkhatib A, Berry GJ, et al. Using Bronchoscopic Lung Cryobiopsy and a Genomic Classifier in the Multidisciplinary Diagnosis of Diffuse Interstitial Lung Diseases. Chest. 2020;158(5):2015–2025. doi:10.1016/j.chest.2020.05.532.
   Web of Science ®Google Scholar
• Richeldi L, Scholand MB, Lynch DA, et al. Utility of a Molecular Classifier as a Complement to HRCT to Identify Usual Interstitial Pneumonia. Am J Respir Crit Care Med. 2020;203(2):211–220. doi:10.1164/rccm.202003-0877OC.
   Web of Science ®Google Scholar
• Wells AU, Flaherty KR, Brown KK, INBUILD trial investigators, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453–460. doi:10.1016/S2213-2600(20)30036-9.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Kolb M, Jouneau S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20(1):3 doi:10.1186/s12890-019-1030-4.
   PubMed Web of Science ®Google Scholar
• Patel N, Kaner R, Cerri S, et al. Effect of Nintedanib in patients with progressive fibrosing ILDs and preserved lung function at baseline: further analyses of the INBUILD trial. Abstract Presented at CHEST 2020 Annual Meeting OCTOBER 18-21, 2020, 2020.
   Google Scholar
• Krauss E, Tello S, Wilhelm J, et al. Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg). J Clin Med. 2020;9(11):3763. doi:10.3390/jcm9113763
   Web of Science ®Google Scholar
• Behr J, Prasse A, Wirtz H, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020;56(2):1902279. doi:10.1183/13993003.02279-2019.
   Web of Science ®Google Scholar
• Moor CC, Mostard RLM, Grutters JC, et al. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. Respir Res. 2020;21(1):196. doi:10.1186/s12931-020-01458-1.
   PubMed Web of Science ®Google Scholar
• Hatabu H, Hunninghake GM, Richeldi L, et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med. 2020;8(7):726–737. doi:10.1016/S2213-2600(20)30168-5.
   PubMed Web of Science ®Google Scholar
• Moor CC, Oppenheimer JC, Nakshbandi G, et al. Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. Eur Respir J. 2021;57:2002042.
   Web of Science ®Google Scholar
• Richeldi L, Fernandez Perez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(1):25–33. doi:10.1016/S2213-2600(19)30262-0.
   PubMed Web of Science ®Google Scholar
• Esposito AJ, Menon AA, Ghosh AJ, et al. Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case-Control Study. Am J Respir Crit Care Med. 2020;202(12):1710–1713. doi:10.1164/rccm.202006-2441LE.
   PubMed Web of Science ®Google Scholar
• Gallay L, Uzunhan Y, Borie R, et al. Risk Factors for Mortality Following COVID-19 in Patients with Pre-existing Interstitial Lung Disease. Am J Respir Crit Care Med. 2021;203(2):245–249. doi:10.1164/rccm.202007-2638LE.
   Web of Science ®Google Scholar
• Drake TM, Docherty AB, Harrison EM, et al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med. 2020;202(12):1656–1665. doi:10.1164/rccm.202007-2794OC.
   PubMed Web of Science ®Google Scholar
• Koyauchi T, Suzuki Y, Sato K, et al. Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study. Thorax. 2021;76(3):248–255. doi:10.1136/thoraxjnl-2020-215917.
   Web of Science ®Google Scholar
• Archibald N, Bakal JA, Richman-Eisenstat J, Kalluri M. Early Integrated Palliative Care Bundle Impacts Location of Death in Interstitial Lung Disease: A Pilot Retrospective Study. Am J Hosp Palliat Care. 2021;38(2):104–113. doi:10.1177/1049909120924995.
   Web of Science ®Google Scholar